Lead sponsor
National Institute on Drug Abuse (NIDA)
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
2
Trials led
2
Active
180
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
2
Trials by status
Not yet recruiting
1
Recruiting
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment